FDA on confusing drug names and the Second Circuits on rogue science

This week, Jan Dodd, a partner in Los Angeles whose practice focuses on advising pharmaceutical, medical device, and manufacturing companies on product liability lawsuits and risk mitigation, discusses:

• FDA guidance
• Drug pricing
• Daubert
• Securities class action
• Did you know?